A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for Ovarian Cancer
24 locations incl. La Jolla
Sponsor: AbbVie
Sex: Female·Age: 18+
Code: NCT07059845·Phase 2·Recruiting·Listed Jul 2025